Previous Close | 4.2650 |
Open | 3.1900 |
Bid | 2.9200 x 1300 |
Ask | 2.9400 x 2200 |
Day's Range | 2.7500 - 3.2790 |
52 Week Range | 0.1300 - 3.2790 |
Volume | |
Avg. Volume | 8,106,603 |
Market Cap | 243.34M |
Beta (5Y Monthly) | 1.00 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4880 |
Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jan 12, 2016 |
1y Target Est | 1.07 |
PolarityTE, Inc. (PTE) delivered earnings and revenue surprises of -25% and 12.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), PolarityTE, Inc. (NASDAQ: PTE) Veru Inc. (NASDAQ: VERU), and PharmaDrug (OTC: LMLLF) (CSE: PHRX). As the global pharma market surpasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new exponential grow
NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: PolarityTE, Inc. (NASDAQ: PTE), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), atai Life Sciences N.V. (NASDAQ: ATAI), and LIXTE Biotechnology (NASDAQ: LIXT). As the global pharma market surpasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new e